Apomorphine: An underutilized therapy for Parkinson's disease

Movement Disorders

Volumn 15, Issue 5, 2000, Pages 789-794

  Merims, Doron ^a   Galili Mosberg, Ronit ^a   Melamed, Eldad ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Apomorphine; Dyskinesias; Motor fluctuations; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

CONTINUOUS INFUSION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG POTENCY; DRUG TOLERABILITY; DYSKINESIA; FEMALE SEXUAL DYSFUNCTION; FOLLOW UP; HALLUCINATION; HEMOLYTIC ANEMIA; HUMAN; HYPOMANIA; MENTAL DISEASE; MONOTHERAPY; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; STOMATITIS; SYMPTOMATOLOGY; VOMITING;

ANTIPARKINSON AGENTS; APOMORPHINE; CONTROLLED CLINICAL TRIALS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FOLLOW-UP STUDIES; HUMAN; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 0033819538     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H     Document Type: Review

References (58)

1. The natural history of Parkinson's disease
2. Recent advances in the drug treatment of Parkinson's disease
3. Researches into the chemical constitution of the opium bases. Part 1: On the action of hydrochloric acid on morphia
4. De l'apomorphine dans certain troubles nerveux
5. Apomorphine in Parkinson's disease
6. Untersuchungen Uber die Wirkungsweise des Apomorphins auf den Parkinsontremor
7. Similarities between neurological effects of L-dopa and of apomorphine
8. Treatment of Parkinson's disease with apomorphines: Possible role of growth hormone
9. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease
10. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study
11. Apomorphine protects against MPTP-induced neurotoxicity in mice
12. Subcutaneous apomorphine in parkinsonian on-off oscillations
13. Subcutaneous apomorphine in Parkinson's disease
14. Administration souscutanee d'apomorphine dans les fluctuations motrices de la maladie de parkinson
15. Subcutaneous apomorphine in the treatment of Parkinson's disease
16. Subcutaneous apomorphine in Parkinson's disease; response to chronic administration for up to five years
17. The clinical use of apomorphine in Parkinson's disease
18. Subcutaneous apomorphine in late stage Parkinson's disease: A long term follow-up
19. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease
20. Pen injected apomorphine against off phenomena in late Parkinson's disease: A double blind, placebo controlled study
21. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term experience in 20 patients
22. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease
23. Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson's disease
24. Apomorphine-induced penile erections in Parkinson's disease
25. Injected apomorphine and orally administered levodopa in parkinsonism
26. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease
27. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease
28. Pathophysiology of L-dopa-induced dyskinesias
29. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates
30. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: In situ hybridization histochemical an
31. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: Effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content
32. Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease
33. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations
34. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease
35. Comparison of motor response to apomorphine and levodopa in Parkinson's disease
36. Clinical usefulness of apomorphine in movement disorders
37. Apomorfina
38. Apomorphine and lisuride infusion. A comparative chronic study
39. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients
40. Apomorphine infusional therapy in Parkinson's disease: Clinical utility and lack of tolerance
41. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International pramipexole-bromocriptine study group
42. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations
43. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
44. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease
45. Parallel double-blind study of pergolide in Parkinson's disease
46. Double-blind trial of pergolide for Parkinson's disease
47. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study
48. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study
49. Cabergoline in Parkinson's disease complicated by motor fluctuations
50. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations
51. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole study group
52. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone fluctuator study group I
53. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with wearing-off phenomenon: A multicenter, double-blind, randomized, placebo-controlled trial
54. Tolcapone improves motor function in parkinsonian patients with the wearing-off phenomenon: A double-blind, placebo-controlled, multicenter trial
55. Catechol-O-methyltransferase inhibition with tolcapone reduces the wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients
56. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Tolcapone fluctuator study group III
57. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
58. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt study group